Clinical trials: Recurrent Colon Cancer
Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
This phase II trial studies how well TAS-102, irinotecan, and bevacizumab work in treating patients with pre-treated colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery…
- Conditions
- Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Recurrent Colon Adenocarcinoma
- Trial name
- NCT04109924
- Testing
- Irinotecan, Bevacizumab, Trifluridine and Tipiracil Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Roswell Park Cancer Institute
Liver Metastases, Recurrent Colon Cancer
Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
RATIONALE: Drugs used in chemotherapy, such as floxuridine and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer
- Trial name
- NCT00645710
- Testing
- gemcitabine hydrochloride, floxuridine, proteomic profiling
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as liposomal SN-38, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00311610
- Testing
- SN-38 liposome
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lynch Syndrome, Recurrent Endometrial Carcinoma
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
This clinical trial evaluates the effect of tislelizumab in treating patients with mismatch repair deficient endometrial cancer that has come back (recurrent).
- Conditions
- Lynch Syndrome, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinosarcoma
- Trial name
- NCT04906382
- Testing
- Biopsy, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Floor Backes, MD
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)